MA42692A - Compositions biopharmaceutiques - Google Patents

Compositions biopharmaceutiques

Info

Publication number
MA42692A
MA42692A MA042692A MA42692A MA42692A MA 42692 A MA42692 A MA 42692A MA 042692 A MA042692 A MA 042692A MA 42692 A MA42692 A MA 42692A MA 42692 A MA42692 A MA 42692A
Authority
MA
Morocco
Prior art keywords
biopharmaceutical compositions
biopharmaceutical
compositions
Prior art date
Application number
MA042692A
Other languages
English (en)
Inventor
Narendra B Bam
Jennifer Dally
Myrna A Monck
Michelle Spatara
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56877084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42692(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MA42692A publication Critical patent/MA42692A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA042692A 2015-08-24 2016-08-22 Compositions biopharmaceutiques MA42692A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562209000P 2015-08-24 2015-08-24
US201562240131P 2015-10-12 2015-10-12
US201562247906P 2015-10-29 2015-10-29
US201562249497P 2015-11-02 2015-11-02

Publications (1)

Publication Number Publication Date
MA42692A true MA42692A (fr) 2018-07-04

Family

ID=56877084

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042692A MA42692A (fr) 2015-08-24 2016-08-22 Compositions biopharmaceutiques

Country Status (24)

Country Link
US (11) US10870695B2 (fr)
EP (3) EP4056590B1 (fr)
JP (5) JP6821659B2 (fr)
KR (3) KR20250086801A (fr)
CN (5) CN116327921A (fr)
AU (1) AU2016311385C1 (fr)
BR (1) BR112018003741A2 (fr)
CA (1) CA2996088A1 (fr)
CL (1) CL2018000499A1 (fr)
CO (1) CO2018001840A2 (fr)
CR (1) CR20180115A (fr)
DK (1) DK3341409T3 (fr)
DO (1) DOP2018000057A (fr)
EA (1) EA037487B1 (fr)
ES (2) ES3053874T3 (fr)
IL (2) IL326469A (fr)
MA (1) MA42692A (fr)
MX (2) MX2018002319A (fr)
PE (1) PE20181176A1 (fr)
PH (1) PH12018500379B1 (fr)
TW (2) TWI780988B (fr)
UY (1) UY36868A (fr)
WO (1) WO2017033121A1 (fr)
ZA (1) ZA201801158B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3053874T3 (en) 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
CR20180229A (es) 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
CA3026518A1 (fr) * 2016-06-17 2017-12-21 Genentech, Inc. Purification d'anticorps multispecifiques
EA201991552A1 (ru) 2016-12-23 2020-01-09 Сефалон, Инк. Анти-il-5 антитела
SMT202600240T1 (it) * 2017-05-26 2026-07-16 Glaxosmithkline Ip Dev Ltd Composizioni biofarmaceutiche e metodi correlati
CN110913887A (zh) * 2017-06-06 2020-03-24 葛兰素史克有限责任公司 用于儿科患者的生物药物组合物和方法
WO2019062831A1 (fr) 2017-09-29 2019-04-04 江苏恒瑞医药股份有限公司 Anticorps il-5, son fragment liant l'antigène et son utilisation médicale
WO2019224724A1 (fr) * 2018-05-23 2019-11-28 Glaxosmithkline Intellectual Property Development Limited Compositions biopharmaceutiques comprenant des variants d'anticorps
JP7641908B2 (ja) * 2019-03-29 2025-03-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド Il-5に対する抗体を含有する医薬組成物及びその使用
CN114206381A (zh) * 2019-07-10 2022-03-18 瑞泽恩制药公司 宿主细胞蛋白水平降低的合成物及其制备方法
EP4077388A1 (fr) * 2019-12-18 2022-10-26 Tesaro, Inc. Compositions biopharmaceutiques et procédés associés
CN116635417A (zh) * 2020-12-22 2023-08-22 葛兰素史密斯克莱知识产权发展有限公司 白介素5结合蛋白给药方案
CN114870008A (zh) * 2021-02-05 2022-08-09 百奥泰生物制药股份有限公司 一种抗il-5抗体制剂及其制备方法和应用
IL309997A (en) * 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
WO2023049803A1 (fr) * 2021-09-22 2023-03-30 Sonoma Biotherapeutics, Inc. Marqueurs de surface cellulaire d'il5ra

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
WO1995014040A1 (fr) * 1993-11-19 1995-05-26 Baylor College Of Medicine Anticorps monoclonaux specifiques de l'interleukine humaine 5
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
JP2001523083A (ja) 1994-12-23 2001-11-20 スミスクライン・ビーチャム・コーポレイション Il−5により媒介される疾病の治療に有用な組み換えil−5アンタゴニスト
US5683892A (en) 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
GB9712410D0 (en) 1997-06-14 1997-08-13 Glaxo Group Ltd Peptides and compounds that bind to the il-5 receptor
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
WO2005105841A2 (fr) * 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Récepteur humain (ccr5) hdgnr10 de chimiokine de la protéine g
EP1739078A1 (fr) 2005-05-30 2007-01-03 Jerini AG Antagonistes du recepteur C5a
SI1988910T1 (en) 2006-02-28 2018-02-28 Kodiak Sciences Inc. Polymeric conjugates containing acryloyloxyethylphosphorylcholine and their preparations
WO2008134724A2 (fr) 2007-04-30 2008-11-06 Smithkline Beecham Corporation Procédés d'administration d'anticorps anti-il-5
EP2225275A4 (fr) 2007-11-28 2013-04-03 Medimmune Llc Formulation de protéine
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
KR20100134702A (ko) 2008-03-28 2010-12-23 글락소스미스클라인 엘엘씨 치료 방법
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
JP5657224B2 (ja) 2009-08-31 2015-01-21 富士フイルム株式会社 放射線画像検出器の撮像面の設置誤差の程度を判定する方法および装置
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
ES2468827T3 (es) 2010-01-14 2014-06-17 Sanwa Kagaku Kenkyusho Co., Ltd Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada
CN107837395A (zh) 2011-02-09 2018-03-27 葛兰素史密斯克莱有限责任公司 冻干制剂
BR112013025845A2 (pt) 2011-04-07 2018-09-04 Glaxosmithkline Llc formulações com viscosidade reduzida
BR112013025866A2 (pt) 2011-04-07 2016-12-20 Glaxosmithkline Llc formulações com viscosidade reduzida
AU2012332767C1 (en) * 2011-10-31 2017-02-02 Genentech, Inc. Antibody formulations
EP2738172A1 (fr) 2012-11-28 2014-06-04 Almirall, S.A. Nouveaux composés bicycliques utilisés comme modulateurs du canal crac
BR112015017307A2 (pt) * 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
WO2014141149A1 (fr) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations présentant une viscosité réduite
EP2848615A1 (fr) 2013-07-03 2015-03-18 Almirall, S.A. Nouveaux dérivés de pyrazole utilisés comme modulateurs du canal CRAC
WO2015049519A2 (fr) 2013-10-02 2015-04-09 Vectura Limited Procédé et appareil
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
KR102301188B1 (ko) 2014-02-06 2021-09-13 엑스4 파마슈티컬스 (오스트리아) 게엠베하 이. 콜라이 특이성 항체 서열
TW201705961A (zh) 2015-06-11 2017-02-16 阿爾米雷爾有限公司 作為jak抑制劑的2-(吡唑并吡啶-3-基)嘧啶衍生物
ES3053874T3 (en) * 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions

Also Published As

Publication number Publication date
PE20181176A1 (es) 2018-07-20
US20220185878A1 (en) 2022-06-16
EA201890572A1 (ru) 2018-10-31
US20210332125A1 (en) 2021-10-28
US12454571B2 (en) 2025-10-28
CL2018000499A1 (es) 2018-07-06
CO2018001840A2 (es) 2018-05-31
NZ739899A (en) 2025-05-02
JP7463070B2 (ja) 2024-04-08
US20240294630A1 (en) 2024-09-05
EP3341409A1 (fr) 2018-07-04
JP2018526369A (ja) 2018-09-13
US11274148B2 (en) 2022-03-15
EA037487B1 (ru) 2021-04-02
CN116327922A (zh) 2023-06-27
DK3341409T3 (da) 2026-05-18
ES3068083T3 (es) 2026-05-27
US12187791B2 (en) 2025-01-07
US20210340247A1 (en) 2021-11-04
ES3053874T3 (en) 2026-01-27
IL326469A (en) 2026-04-01
US20180251539A1 (en) 2018-09-06
US12187789B2 (en) 2025-01-07
IL257539B2 (en) 2026-07-01
TWI780988B (zh) 2022-10-11
US11459384B2 (en) 2022-10-04
EP4717700A2 (fr) 2026-04-01
DOP2018000057A (es) 2018-03-15
US20240294628A1 (en) 2024-09-05
TW202233238A (zh) 2022-09-01
JP6821659B2 (ja) 2021-01-27
AU2016311385C1 (en) 2019-08-22
CN108137683A (zh) 2018-06-08
US11299541B2 (en) 2022-04-12
TW201722473A (zh) 2017-07-01
JP2022023049A (ja) 2022-02-07
US20200199219A1 (en) 2020-06-25
TWI750133B (zh) 2021-12-21
BR112018003741A2 (en) 2018-09-25
JP2024123040A (ja) 2024-09-10
WO2017033121A1 (fr) 2017-03-02
US11286298B2 (en) 2022-03-29
US12187790B2 (en) 2025-01-07
MX2024001617A (es) 2024-03-06
ZA201801158B (en) 2019-08-28
JP2026053516A (ja) 2026-03-25
US20240294629A1 (en) 2024-09-05
KR20250086801A (ko) 2025-06-13
CN116327921A (zh) 2023-06-27
PH12018500379B1 (en) 2022-11-23
EP4056590A1 (fr) 2022-09-14
UY36868A (es) 2017-03-31
MX2018002319A (es) 2018-04-11
CN116327923A (zh) 2023-06-27
EP3341409B1 (fr) 2026-02-25
JP2020033351A (ja) 2020-03-05
IL257539B1 (en) 2026-03-01
EP4056590B1 (fr) 2025-10-15
US20220380452A1 (en) 2022-12-01
KR20240099511A (ko) 2024-06-28
CR20180115A (es) 2018-04-12
PH12018500379A1 (en) 2018-09-03
AU2016311385A1 (en) 2018-03-15
EP4717700A3 (fr) 2026-06-03
CA2996088A1 (fr) 2017-03-02
IL257539A (en) 2018-04-30
CN116474091A (zh) 2023-07-25
AU2016311385B2 (en) 2019-05-09
US20260049130A1 (en) 2026-02-19
US20210340246A1 (en) 2021-11-04
KR20180037275A (ko) 2018-04-11
US10870695B2 (en) 2020-12-22

Similar Documents

Publication Publication Date Title
NL301348I2 (nl) obecabtagene autoleucel
NO2023005I1 (no) tirzepatide
EP3534968A4 (fr) Compositions de lymphocytes t car anti-bcma
DK3361870T3 (da) Fungicidsammensætninger
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3331528T3 (da) Muskarinagonister
DK3277719T3 (da) Polypeptider
EP3339331A4 (fr) Composition
DK3305788T3 (da) Janus-kinase-hæmmer
PT3298027T (pt) Compostos depsipéptidos antelmínticos
EP3398996A4 (fr) Composition
IL257539A (en) Biopharmaceutical compositions
DK3250182T3 (da) Dispergible sammensætninger
DK3310450T3 (da) Olie-vand-separator
DK3334726T3 (da) Plinabulinsammensætninger
DK3270930T3 (da) Præeklampsi
LT3362444T (lt) Junginiai
EP3395887C0 (fr) Composition de caoutchouc fluoré
DK3322295T3 (da) Sammensætning
DK3597189T3 (da) Krystallinske forbindelser
DK3274482T3 (da) Stenborsknop
DK3347403T3 (da) Polyalkoxyfedtforbindelse
DE112015006486A5 (de) Inkubationsrinne
DK3316857T3 (da) Multifasiske sammensætninger
DK3528791T3 (da) Dispergible sammensætninger